Skip to main content
. Author manuscript; available in PMC: 2019 May 21.
Published in final edited form as: Neuroscience. 2018 Mar 26;379:269–280. doi: 10.1016/j.neuroscience.2018.03.028

Table 1.

EC50 values, fold change and potency of hit compounds obtained from primary and secondary screening that showed significant enhancement in the barrier intactness of bEnd3 monolayer.

Compound Pharmacological activity# EC50 (μM) Fold ↓ in Pc Potency
BrG Activator of cGMP-dependent protein kinases 4.9 0.14 0.03
JW74 Inhibitor of canonical Wnt signaling 3.6 0.27 0.08
Phen Metalloprotease inhibitor 0.4 0.15 0.38
SB2 GSK-3β inhibitor 12.8 0.43 0.03
Tph Potent antioxidant 2.4 0.37 0.15